Compare BMRN & PNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMRN | PNW |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.6B |
| IPO Year | 1999 | N/A |
| Metric | BMRN | PNW |
|---|---|---|
| Price | $59.35 | $87.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $89.74 | ★ $95.73 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 02-18-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 4.13% |
| EPS Growth | ★ 59.53 | N/A |
| EPS | 2.68 | ★ 4.92 |
| Revenue | $3,094,001,000.00 | ★ $5,307,180,000.00 |
| Revenue This Year | $13.35 | $4.96 |
| Revenue Next Year | $9.06 | $4.02 |
| P/E Ratio | $22.18 | ★ $17.92 |
| Revenue Growth | ★ 12.39 | 5.70 |
| 52 Week Low | $50.76 | $81.47 |
| 52 Week High | $73.51 | $96.50 |
| Indicator | BMRN | PNW |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 43.67 |
| Support Level | $58.44 | $86.82 |
| Resistance Level | $59.82 | $89.49 |
| Average True Range (ATR) | 1.99 | 1.02 |
| MACD | 0.28 | 0.06 |
| Stochastic Oscillator | 64.74 | 39.24 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.